Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma

Thorax

Volumn 54, Issue 2, 1999, Pages 108-114

  Jatakanon, Anon ^a   Kharitonov, Sergei ^a   Lim, Sam ^a   Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Airway inflammation; Asthma; Inhaled corticosteroids

Indexed keywords

ANTIASTHMATIC AGENT; BUDESONIDE; METHACHOLINE; NITRIC OXIDE;

ADULT; AIRWAY; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; EOSINOPHIL; EOSINOPHILIA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; MALE; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033060321     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.54.2.108     Document Type: Article

References (37)

1. 1 NHLBI. Guidelines for diagnosis and management of asthma. NIH Publication No. 97-4051A, 1997:17-47.
2. 2 British Thoracic Society. The British guidelines on asthma management. Thorax 1997;52(Suppl 1):S1-21.
3. 3 Sont JK, Han J, van Krieken JM, et al. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax 1096;51:496-502.
4. 4 Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994;331:700-5.
5. 5 Kharitonov SA, Yates D, Robbins RA, et al. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994;343: 133-5.
6. 6 Gibson PG, Girgis Gabardo A, Morris, et al. Cellular characteristics of sputum from patients with asthma and chronic bronchitis. Thorax 1989;44:693-9.
7. 7 Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med 1996;153;454-7.
8. 8 Keatings VM, Jatakanon A, Worsdell YM, et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-8.
9. 9 Claman DM, Boushey HA, Liu J, et al. Analysis of induced sputum to examine the effects of prednisone on airway inflammation in asthmatic subjects. J Allergy Clin Immunol 1994;94:861-9.
10. 10 Jones AH, Langdon CG, Lee PS, et al. Pulmicort Turbohaler once daily as initial prophylactic therapy for asthma. Respir Med 1994;88:293-9.
11. 11 Chai H, Farr RS, Froehlich LA, et al. Standardization of bronchial inhalation challenge procedures. J Allergy Clin Immunol 1975;56:323-7.
12. 12 Kharitonov SA, Chung KF, Evans D, et al. Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. Am J Respir Crit Care Med 1996;153:1773-80.
13. 13 Jatakanon A, Lim S, Kharitonov SA, et al. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax 1998;53:91-5.
14. 14 Armitage P, Berry G. Statistical methods in medical research. Oxford: Blackwell Scientific, 1994: 245-9.
15. 15 Altman DG. Practical statistics for medical research. London: Chapman & Hall, 1991: 215-7.
16. 16 Gershman NH, Wong HH, Liu JT, et al. Comparison of two methods of collecting induced sputum in asthmatic subjects. Eur Respir J 1996;9:2448-53.
17. 17 in't Veen JC, de Gouw HW, Smits HH, et al. Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma. Eur Respir J 1996;9: 2441-7.
18. 18 Pizzichini E, Pizzichini MM, Efthimiadis A, et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996;154:308-17.
19. 19 Pizzichini E, Pizzichini MM, Efthimiadis A, et al. Measuring airway inflammation in asthma: eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood. J Allergy Clin Immunol 1997;99:539 44.
20. 20 Gibson PG, Wong BJ, Hepperle MJ, et al. A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid. Clin Exp Allergy 1992;22:525-32.
21. 21 Pizzichini MM, Pizzichini E, Clelland L, et al. Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med 1997;155:1501-8.
22. 22 Lamas AM, Leon OG, Schleimer RP. Glucocorticoids inhibit eosinophil responses to granulocyte-macrophage colony-stimulating factor. J Immunol 1991;147:254-9.
23. 23 Wallen N, Kita H, Weiler D, et al. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol 1991; 147:3490-5.
24. 24 Hallsworth MP, Litchfield TM, Lee TH. Glucocorticoids inhibit granulocyte-macrophage colony-stimulating factor-1 and interleukin-5 enhanced in vitro survival of human eosinophils. Immunology 1992;75:382-5.
25. 25 Baigelman W, Chodosh S, Pizzuto D, et al. A. Sputum and blood eosinophils during corticosteroid treatment of acute exacerbations of asthma. Am J Med 1983;75:929-36.
26. 26 Corrigan CJ, Hamid Q, North J, et al. Peripheral blood CD4 but not CD8 T-lymphocytes in patients with exacerbation of asthma transcribe and translate messenger RNA encoding cytokines which prolong eosinophil survival in the context of a Th2-type pattern: effect of glucocorticoid therapy. Am J Respir Cell Mol Biol 1995;12:567-78.
27. 27 Busse WW, Chervinsky P, Condemi J, et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998;101:457-63.
28. 28 Campbell LM, Gunn SD, Sweeney D, et al. Once daily budesonide: effective control of moderately severe asthma with 800 μg once daily inhaled via Turbohaler when compared with 400 μg twice daily. Eur J Clin Res 1995;7:1-14.
29. 29 Juniper EF, Kline PA, Vanzieleghem MA, et al. Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur Respir J 1990;3:1122-7.
30. 30 Barnes PJ. New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. J Allergy Clin Immunol 1989;83:1013-26.
31. 31 Vathenen AS, Knox AJ, Wisniewski A, et al. Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis 1991;143:1317-21.
32. 32 Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990;142:832-6.
33. 33 van Essen Zandvliet EE, Hughes MD, et al. Effects of 22 months of treatment with inhaled corticosteroids and or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma The Dutch Chronic Non-specific Lung Disease Study Group. Am Rev Respir Dis 1992;146:547-54.
34. 34 Kerstjens HA, Brand PL, Hughes MD, et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. N Engl J Med 1992;327:1413-9.
35. 35 Kraan J, Koeter GH, van der Mark ?, et al. Dosage and time effects of inhaled budesonide on bronchial hyperreactivity. Am Rev Respir Dis 1988;137:44-8.
36. 36 Booth H, Richmond I, Ward C, et al. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Am J Respir Crit Care Med 1995;152:45-52.
37. 37 Boulet LP, Laviolette M, Turcotte H, et al. Bronchial subepithelial fibrosis correlates with airway responsiveness to methacholine. Chest 1997;112:45-52.